Drugs / CSCC_ASC
CSCC_ASC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02387723 | Dec 2014 → Nov 2015 | heart failure | JKastrup | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT03797092 Comparator | Oct 2019 → Jul 2021 | dilated cardiomyopathy | JKastrup | Unknown | No outcome recorded |
| Phase 2 | NCT02673164 Comparator | Jan 2017 → Dec 2020 | heart failure | JKastrup | Completed | No outcome recorded |
| Phase 2 | NCT03092284 Comparator | Sep 2015 → Jul 2021 | heart failure | JKastrup | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSCC_ASC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02387723 ↗ |
| Known as | Allogeneic adipose derived stem cells | “Allogeneic adipose derived stem cells (CSCC_ASC)” NCT02387723 ↗ |
| Known as | Cardiology Stem Cell Centre Adipose Stem Cell | “Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)” NCT03092284 ↗ |
| Modality | Cell therapy | “allogeneic adipose tissue derived mesenchymal stem cells” NCT02387723 ↗ |
| Route | Other | “The cells will be injected directly into the myocardium” NCT02387723 ↗ |